1-4 of 4
Carolyn Jane Owen, MD FRCPC
Close
Sort by
Journal Articles

Venetoclax Plus Rituximab Is Superior to Bendamustine Plus Rituximab in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia - Results from Pre-Planned Interim Analysis of the Randomized Phase 3 Murano Study

John F Seymour, MBBS, PhD, Thomas J. Kipps, MD, Barbara F. Eichhorst, MD, Peter Hillmen, MBChB, FRCP, FRCPath, PhD, James M. D'Rozario, MBBS FRACP FRCPA, Sarit Assouline, MD, Carolyn Jane Owen, MD FRCPC, John Gerecitano, MD PhD, Tadeusz Robak, MD PhD, Javier De la Serna, MD, Ulrich Jaeger, MD, Guillaume Cartron, MD PhD, Marco Montillo, MD, Rod Humerickhouse, MD PhD, Elizabeth Punnoose, PhD, Yan Li, PhD, Michelle Boyer, PhD, Kathryn Humphrey, BSc, Mehrdad Mobasher, MD, MPH, Arnon P. Kater, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): LBA-2.
https://doi.org/10.1182/blood.V130.Suppl_1.LBA-2.LBA-2
Published: 2017
Journal Articles

A Phase II Clinical Trial of the Pan PI3K Inhibitor, Buparlisib, for the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia: Canadian Cancer Trials Group IND.216

Sarit Assouline, MD, Lilian Amrein, PhD, Versha Banerji, MD FRCP, Stephen Caplan, MD, Carolyn Jane Owen, MD FRCPC, Wanda Hasegawa, MD, Sue Robinson, MD, Sudeep Shavikumar, MD, Anca Prica, MD FRCP(C), Anthea Peters, MSc, MD FRCPC, Linda Hagerman, Laura Rodriguez, Tanya Skamene, MD, Lawrence Panasci, MD, Bingshu E. Chen, Annette E Hay
Journal: Blood
Blood (2017) 130 (Supplement 1): 4319.
https://doi.org/10.1182/blood.V130.Suppl_1.4319.4319
Published: 2017
Journal Articles

Prolonged Improvement in Patient-Reported Outcomes (PROs) and Well-being in Older Patients With Treatment-Naïve (TN) Chronic Lymphocytic Leukemia Treated With Ibrutinib (Ibr): 3-Year Follow-up of the RESONATE-2 Study

Alessandra Tedeschi, MD, Carolyn Jane Owen, MD FRCPC, Tadeusz Robak, MD PhD, Paul M. Barr, MD, Osnat Bairey, MD, Peter Hillmen, MBChB, PhD, Steven Coutre, MD, Stephen Devereux, FRCP, FRCPath, PhD, Sebastian Grosicki, MD PhD, Helen McCarthy, MBBS, PhD, Jianyong Li, MD, David Simpson, MBChB, Tanya Siddiqi, MD, Giri Iyer, MBA, Indu D. Lal, MD, Jeremiah Trudeau, PhD, Sandra Dai, PhD, James P. Dean, MD PhD, Danelle F. James, MD MAS, Jan A. Burger, MD PhD, Paolo Ghia, MD PhD, Thomas J. Kipps, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1746.
https://doi.org/10.1182/blood.V130.Suppl_1.1746.1746
Published: 2017
Journal Articles

Single-Agent Ibrutinib Vs Chemoimmunotherapy Regimens for Treatment-Naïve Patients with Chronic Lymphocytic Leukemia (CLL): A Cross-Trial Comparison

Tadeusz Robak, MD PhD, Jan A. Burger, MD PhD, Alessandra Tedeschi, MD, Paul M. Barr, MD, Carolyn Jane Owen, MD FRCPC, Osnat Bairey, MD, Peter Hillmen, MBChB, PhD, David Simpson, MBChB, Sebastian Grosicki, MD PhD, Stephen Devereux, FRCP, FRCPath, PhD, Helen McCarthy, MBBS, PhD, Steven Coutre, MD, Hang Quach, MBBS, MD, Gianluca Gaidano, MD PhD, Zvenyslava Maslyak, MD, Don A Stevens, MD, Carol Moreno, MD, Devinder Gill, MD, Ian W. Flinn, MD PhD, John Gribben, MD DSc, Ahmad Mokatrin, PhD, Mei Cheng, PhD, Lori Styles, MD, Danelle F. James, MD MAS, Thomas J. Kipps, MD, Paolo Ghia, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1750.
https://doi.org/10.1182/blood.V130.Suppl_1.1750.1750
Published: 2017